Clinical trials: Lung Fibrosis Interstitial
Idiopathic Pulmonary Fibrosis
A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study of vismodegib in patients with IPF. Eligible patients will be randomized in a 2:1 ratio to one of two treatment arms: vismodegib or…
- Trial name
- NCT02168530
- Testing
- vismodegib
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis, Lung Disease
The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in…
- Conditions
- Idiopathic Pulmonary Fibrosis, Lung Disease, Pulmonary Fibrosis
- Trial name
- NCT00075998
- Testing
- Interferon gamma-1b ("Actimmune")
- Where
- United States
- Volunteers
- 826 people
- Sponsor
- InterMune
Pulmonary Hypertension, Interstitial Lung Disease
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02630316
- Testing
- Inhaled Treprostinil
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis
Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects
The current study will investigate the initial safety, tolerability, and PK profile of inhaled LTI-03 in healthy volunteers. In order to minimize exposure, the study will first test single ascending doses (SAD) of LTI-03 followed…
- Trial name
- NCT04233814
- Testing
- Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
- Where
- United Kingdom
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Rein Therapeutics
Pulmonary Fibrosis
A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects
This is a phase Ⅰ study to evaluate the relative bioavailability of HRS-9813 capsule and tablet in healthy subjects and the effect of food on the pharmacokinetics of HRS-9813 capsule.
- Trial name
- NCT06939504
- Testing
- HRS-9813 Capsule, HRS-9813 Tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical study conducted in China to compare the efficacy and safety of two different dose groups of AK3280 in IPF patients compared to the…
- Trial name
- NCT05424887
- Testing
- AK3280
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
- Trial name
- TETON-1 (NCT04708782)
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 98 sites in United States, Canada and 1 more
- Volunteers
- 598 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis
Safety and Effectiveness of Nintedanib in Korean Patients
The objectives of this study are to monitor the safety and effectiveness of Ofev in Korean patients in a routine clinical practice setting.
- Trial name
- NCT04525547
- Testing
- Nintedanib
- Where
- 22 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Diopathic Pulmonary Fibrosis, Pulmonary Fibrosis
The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011,in health conditions.
- Trial name
- NCT06160440
- Testing
- SC1011
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis…
- Trial name
- STARSCAPE (NCT04552899)
- Testing
- PRM-151 (Zinpentraxin Alfa)
- Where
- 360 sites in United States, Argentina and 33 more
- Volunteers
- 665 people
- Sponsor
- Hoffmann-La Roche
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
The primary objective of this study is to evaluate the effect of 52 weeks of once daily treatment with TPIP compared with placebo on lung function in adults with PPF.
- Trial name
- PALM-PPF (NCT07805785)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Insmed Incorporated
Lung Diseases, Interstitial
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
- Trial name
- NCT03313180
- Testing
- Nintedanib
- Where
- 159 sites in United States, Argentina and 28 more
- Volunteers
- 444 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis (IPF)
Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
- Trial name
- IPF (NCT07728721)
- Testing
- HSK50042 dose 1, HSK50042 dose 2, HSK50042 dose 3
- Volunteers
- 175 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
This is a phase 3 clinical study conducted in China. The primary objective is to compare the efficacy and safety of AK3280 400 mg versus placebo and active control (pirfenidone) in IPF patients.
- Trial name
- NCT07719023
- Testing
- AK3280, Pirfenidone
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
This international clinical study will enroll participants with a suspected diagnosis of IPF/ILD. This study will characterize the disease behavior of IPF and ILD in the peri-diagnostic period.
- Trial name
- NCT03261037
- Testing
- Spirometry, Accelerometry, 6MWT
- Where
- 37 sites in Canada, France and 4 more
- Volunteers
- 178 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.
- Trial name
- FGCL-3019-049 (NCT01262001)
- Testing
- FG-3019
- Where
- 18 sites in United States
- Volunteers
- 90 people
- Sponsor
- Kyntra Bio
Idiopathic Pulmonary Fibrosis (IPF)
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after…
- Trial name
- NCT03981094
- Testing
- BMS-986278, Pirfenidone
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF
A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.
- Trial name
- NCT03538301
- Testing
- ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose)
- Where
- 33 sites in United States, Germany and 2 more
- Volunteers
- 123 people
- Sponsor
- Nitto Denko Corporation
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- OCEAN-1 (NCT07671911)
- Testing
- NAL ER
- Where
- 22 sites in United States
- Volunteers
- 306 people
- Sponsor
- Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months.
- Trial name
- NCT02058602
- Testing
- Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline